Protective effects of GR-103691-related compound on the stroke mouse model
Project/Area Number |
26460106
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Pharmacology in pharmacy
|
Research Institution | Nihon University |
Principal Investigator |
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
Keywords | 脳梗塞 / GR103691 / 行動薬理試験 / 脳保護薬 |
Outline of Final Research Achievements |
In the stroke mouse model induced by rose bengal injection and irradiation (IR) of middle cerebral artery, the ischemic volume of 24 h after IR by TTC staining enlarged from 1 h, however, the difference was not observed 72 h after. Latency to fall in rotor rod test decreased for 1 h and 24 h after ischemia, and recovered to a sham level 48 h after. In contrast, The spontaneous motor activities (locomotor and vertical activities) and neuropathy scores assessed by posture, tail suspension test and platform walk test were dramatically damaged 1 h after IR, and then slowly recovered. There is a significant difference in these index between sham and ischemic group even after 72 h. In addition, significant correlation between the ischemic volume and neuropathy score 72 h after IR was observed. Edaravone and a GR103691-related compound decreased ischemic volume and suppressed behavioral damage. These data suggests that a GR103691-related compound will be lead compound for treatment of stroke.
|
Report
(4 results)
Research Products
(3 results)